Total Payments
$393,864
2024 Payments
$45,944
Companies
15
Transactions
728
Medicare Patients
2,150
Medicare Billing
$265,805
Payment Breakdown by Category
Other$293,972 (74.6%)
Consulting$42,025 (10.7%)
Travel$28,910 (7.3%)
Research$16,660 (4.2%)
Food & Beverage$12,283 (3.1%)
Education$13.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $195,907 | 121 | 49.7% |
| Honoraria | $98,066 | 43 | 24.9% |
| Consulting Fee | $42,025 | 16 | 10.7% |
| Travel and Lodging | $28,910 | 124 | 7.3% |
| Unspecified | $16,660 | 11 | 4.2% |
| Food and Beverage | $12,283 | 411 | 3.1% |
| Education | $13.10 | 2 | 0.0% |
Payments by Type
General
$377,204
717 transactions
Research
$16,660
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $203,882 | 422 | $0 (2024) |
| SK Life Science, Inc. | $96,986 | 95 | $0 (2024) |
| EISAI INC. | $33,255 | 51 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $27,887 | 74 | $0 (2022) |
| Lundbeck LLC | $19,707 | 38 | $0 (2018) |
| JAZZ PHARMACEUTICALS INC. | $4,299 | 14 | $0 (2024) |
| Biocodex, Inc. | $3,180 | 3 | $0 (2023) |
| AQUESTIVE THERAPEUTICS, INC. | $2,791 | 5 | $0 (2020) |
| Supernus Pharmaceuticals, Inc. | $1,598 | 12 | $0 (2020) |
| Greenwich Biosciences, Inc. | $128.55 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,944 | 58 | UCB, Inc. ($34,106) |
| 2023 | $55,694 | 93 | SK Life Science, Inc. ($37,468) |
| 2022 | $49,501 | 105 | SK Life Science, Inc. ($27,939) |
| 2021 | $26,286 | 54 | SK Life Science, Inc. ($13,462) |
| 2020 | $36,038 | 60 | UCB, Inc. ($22,305) |
| 2019 | $30,055 | 83 | UCB, Inc. ($15,149) |
| 2018 | $69,050 | 133 | UCB, Inc. ($42,791) |
| 2017 | $81,297 | 142 | UCB, Inc. ($49,056) |
All Payment Transactions
728 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $38.23 | General |
| Category: Neurology | ||||||
| 12/19/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: Neurology | ||||||
| 12/14/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $33.58 | General |
| Category: Neurology | ||||||
| 12/10/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $140.35 | General |
| Category: Neurology | ||||||
| 12/05/2024 | UCB, Inc. | Fintepla (Drug) | Travel and Lodging | Cash or cash equivalent | $66.00 | General |
| Category: Neurology | ||||||
| 11/06/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| Category: Neurology | ||||||
| 11/06/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $105.27 | General |
| Category: Neurology | ||||||
| 10/25/2024 | UCB, Inc. | Fintepla (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Neurology | ||||||
| 10/19/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: Neurology | ||||||
| 10/05/2024 | UCB, Inc. | Fintepla (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: Neurology | ||||||
| 10/05/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Neurology | ||||||
| 10/05/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Neurology | ||||||
| 10/05/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Neurology | ||||||
| 10/04/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $138.00 | General |
| Category: Neurology | ||||||
| 09/27/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: Neurology | ||||||
| 09/20/2024 | SK Life Science, Inc. | XCOPRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Neurology | ||||||
| 09/20/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: NEUROLOGY | ||||||
| 09/19/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $4.84 | General |
| Category: Neurology | ||||||
| 09/18/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Neurology | ||||||
| 09/17/2024 | UCB, Inc. | Nayzilam (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: Neurology | ||||||
| 09/14/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Neurology | ||||||
| 09/12/2024 | UCB, Inc. | Nayzilam (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: Neurology | ||||||
| 09/11/2024 | UCB, Inc. | Fintepla (Drug) | Travel and Lodging | In-kind items and services | $576.95 | General |
| Category: Neurology | ||||||
| 09/05/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $123.13 | General |
| Category: Neurology | ||||||
| 08/29/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $115.72 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program | UCB, Inc. | $2,300 | 1 |
| Brivaracetam-induced elevation of carbamazepine-epoxide levels: a post-hoc analysis from the clinical development program | UCB, Inc. | $2,300 | 1 |
| Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, Phase III studies | UCB, Inc. | $2,300 | 1 |
| Long-term safety and efficacy of brivaracetam in adults with focal seizures Results from an open-label, multinational, follow-up trial | UCB, Inc. | $2,300 | 1 |
| Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial | UCB, Inc. | $2,300 | 1 |
| Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial | UCB, Inc. | $2,300 | 1 |
| Long-term follow-up study of patients with epilepsy who switched from adjunctive levetiracetam to brivaracetam | UCB, Inc. | $1,220 | 2 |
| Safety and tolerability of long-term brivaracetam monotherapy in patients with focal seizures | UCB, Inc. | $820.00 | 2 |
| Somnolence and time to return to baseline functionality after midazolam nasal spray delivery in patients with seizure clusters: post hoc analysis of a randomized, double-blind, placebo-controlled trial | UCB, Inc. | $820.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 427 | 643 | $145,967 | $51,263 |
| 2022 | 12 | 489 | 681 | $157,193 | $55,070 |
| 2021 | 13 | 564 | 838 | $188,892 | $66,948 |
| 2020 | 14 | 670 | 1,021 | $242,463 | $92,524 |
Total Patients
2,150
Total Services
3,183
Medicare Billing
$265,805
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 60 | 172 | $68,284 | $25,693 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 181 | $31,132 | $9,627 | 30.9% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 58 | 61 | $15,738 | $5,958 | 37.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 32 | 61 | $4,575 | $2,173 | 47.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 33 | 34 | $4,658 | $2,057 | 44.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 35 | 36 | $6,912 | $1,857 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 25 | $6,075 | $1,626 | 26.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $5,145 | $1,481 | 28.8% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 26 | 44 | $1,628 | $481.78 | 29.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 14 | $1,820 | $308.43 | 16.9% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 68 | 175 | $69,409 | $26,671 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 137 | 182 | $31,254 | $7,943 | 25.4% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2022 | 66 | 69 | $17,795 | $7,030 | 39.5% |
| 99218 | Initial hospital observation care per day, typically 30 minutes | Facility | 2022 | 37 | 38 | $7,144 | $2,799 | 39.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 20 | $6,860 | $2,555 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 22 | $5,346 | $1,754 | 32.8% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 31 | 31 | $4,216 | $1,662 | 39.4% |
| 99224 | Follow-up observation care per day, typically 15 minutes | Facility | 2022 | 32 | 47 | $3,525 | $1,384 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $3,498 | $1,377 | 39.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 18 | 19 | $3,249 | $839.60 | 25.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 19 | 26 | $3,380 | $716.81 | 21.2% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2022 | 28 | 41 | $1,517 | $339.68 | 22.4% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 83 | 211 | $85,877 | $32,047 | 37.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 147 | 233 | $39,580 | $12,445 | 31.4% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 77 | 84 | $22,096 | $8,515 | 38.5% |
About Dr. Toufic Fakhoury, MD
Dr. Toufic Fakhoury, MD is a Neurology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235234394.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Toufic Fakhoury, MD has received a total of $393,864 in payments from pharmaceutical and medical device companies, with $45,944 received in 2024. These payments were reported across 728 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($195,907).
As a Medicare-enrolled provider, Fakhoury has provided services to 2,150 Medicare beneficiaries, totaling 3,183 services with total Medicare billing of $265,805. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Lexington, KY
- Active Since 09/13/2006
- Last Updated 07/24/2019
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1235234394
Products in Payments
- Briviact (Drug) $141,337
- XCOPRI (Drug) $90,148
- Nayzilam (Drug) $35,473
- Fycompa (Drug) $32,648
- APTIOM (Drug) $27,606
- ONFI (Drug) $19,685
- Fintepla (Drug) $12,614
- Cenobamate (Drug) $6,451
- Vimpat (Drug) $4,956
- EPIDIOLEX (Drug) $4,299
- DIACOMIT (Drug) $3,180
- SYMPAZAN (Drug) $1,891
- OXTELLAR XR (Drug) $1,581
- LIBERVANT (Drug) $900.00
- Banzel (Drug) $607.50
- BRIVIACT (Drug) $244.65
- LONHALA MAGNAIR (Drug) $219.90
- Epidiolex (Drug) $128.55
- VALTOCO (Drug) $25.99
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $24.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Lexington
Dr. Nicole Everman, M.d, M.D
Neurology — Payments: $506,986
Neurology $506,986
Larry Goldstein, Md, MD
Neurology — Payments: $28,134
Neurology $28,134
Jagannadha Avasarala, Md, Phd, MD, PHD
Neurology — Payments: $26,770
Neurology $26,770
Fred Odago, Md, MD
Neurology — Payments: $22,752
Neurology $22,752
Sharoon Qaiser, M.d, M.D
Neurology — Payments: $19,615
Neurology $19,615
John Slevin, Md, MD
Neurology — Payments: $16,946
Neurology $16,946